Bionomics Investor Presentation Deck

Focused CNS Pipeline with Multiple Potential Catalysts on the Horizon Program BNC210 a7 receptor NAM EmpathBio MERCK Collaboration a7 receptor PAM Nav1.7/1.8 Inhibitors Candidate Kv3.1/3.2 Activators Series Lead Bionomics Indication Social Anxiety Disorder (SAD) Post-Traumatic Stress Disorder (PTSD) +MDMA derivative EMP-01 (PTSD) 2 candidates for cognitive deficits in Alzheimer's Chronic Pain Cognitive Impairment NAM = Negative Allosteric Modulator PAM = Positive Allosteric Modulator Pre-Clinical Phase 1 Phase 2 PREVAIL ATTUNE Phase 3 Memorandum of Understanding to explore combination treatment regimen for PTSD FDA Fast Track designation Status Study underway Topline Data: YE'22 Study underway Topline Data: 1H'23 Feasibility studies ongoing Phase 1 safety & biomarker studies ongoing Pending Pending 4

View entire presentation